topic from-the-ceo 
Pharmaceutical Technology
JULY 19, 2022
as a topical treatment of nonsegmental vitiligo in adults and paediatric patients aged 12 years and above. Opzelura is a topical formulation of a Janus kinase (JAK) inhibitor. In non-segmental vitiligo patients, it is indicated for continuous topical use twice a day to affected regions of up to 10% body surface area.
Pharma Marketing Network
DECEMBER 20, 2021
Lewis, Founder and CEO of eHealthcare Solutions and Tap Native and the Chief Collaborator at Pharma Marketing Network, moderated a deep dive discussion on the topic of physician-level data (PLD) with a focus around drivers for the tool, its usage, and successes learnings about its function in pharma, and the where it’s heading.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JUNE 6, 2023
It’s a topic that has garnered increasing attention in recent years , and one that has raised thorny questions about the balance between conducting open, collaborative science and protecting intellectual property. “Despite what you see in the movies, it is not somebody walking in and saying, ‘Do you want to spy for me?’
Pharmaceutical Technology
JULY 12, 2022
It has attained proof-of-concept with favourable safety and efficacy data from an ongoing Phase I/II clinical trial which is currently enrolling and dosing participants. Topic sponsors are not involved in the creation of editorial content. Subject to necessary conditions, the transaction is anticipated to conclude later this year.
pharmaphorum
AUGUST 17, 2021
In latest episode of our Health Innovators video interview series, Dr Paul Tunnah speaks to Daphne Zohar, the co-founder and CEO of PureTech Health. Daphne Zohar is PureTech’s founder and CEO and a member of its board of directors. Daphne Zohar is PureTech’s founder and CEO and a member of its board of directors.
Pharmaceutical Technology
MAY 23, 2023
The company expects that the proceeds obtained from the deal will extend its cash runway into the fourth quarter of 2024. In 2022, Avrobio’s investigational gene therapy, AVR-RD-04, received a rare paediatric disease designation from the US Food and Drug Administration.
Pharmaceutical Technology
DECEMBER 5, 2022
According to the deal, Incyte is entitled to receive an upfront payment from CMS, which will also make further potential payments on meeting development, regulatory and commercial milestones. Ruxolitinib cream is the first topical inhibitor of JAK to obtain approval in the US.
Expert insights. Personalized for you.
116 
Let's personalize your content